Agile Sciences Adds Two Members to Company's Board of Directors
Agile Sciences enhances pharmaceutical expertise with addition of new Board members
August 22, 2013 (Newswire.com) - Agile Sciences announced today that Dr. Steven Young and Dr. Jeffrey Collins will join the Company's Board of Directors. Both new members bring substantial expertise in pharmaceutical development to Agile Sciences.
Dr. Young is a retired Vice President, Basic Research and former Head of the Department of Medicinal Chemistry at Merck Research Laboratories, West Point, Pennsylvania. During his tenure at Merck, the Medicinal Chemistry Department's programs sought to identify drug candidates for a variety of disease targets, including agents for the treatment of HIV/AIDS, Hepatitis C infection, endocrine problems, sleep disorders, depression, pain, migraine, schizophrenia, and Alzheimer's disease. Dr. Young has been awarded thirty four U.S. patents covering an array of drug candidates.
Dr. Collins is currently an Executive-in-Residence with Pappas Ventures, a life sciences-focused venture capital firm based in RTP. Prior to joining Pappas Ventures in 2002, Dr. Collins served in senior management positions at global clinical research organizations (CROs), including PAREXEL International and ClinTrials Research. Before entering the CRO world, Dr. Collins was at Glaxo, Inc. and Glaxo Wellcome, Inc. for nearly eleven years, where he directed a number of drug development programs in the anti-infectives and oncology areas, resulting in the submission and approval of one NDA and five sNDAs. Dr. Collins also spent four years with the National Toxicology Program at NIEHS as a Project Officer and nearly ten years at the Duke University Medical Center (DUMC), where he taught and conducted research in viral and tumor immunology.
Agile Sciences' Chairman, Dr. Harry Garland, commented, "We are delighted that Dr. Young and Dr. Collins will be joining our Board. Their expertise in drug discovery and pre-clinical and clinical development will be very valuable to Agile Sciences as we advance our pharmaceutical candidates."
About Agile Sciences:
Agile Sciences is headquartered on North Carolina State University's Centennial Campus. The company was founded in 2007 to provide commercial solutions to those industries plagued by the effects of biofilms. The company's proprietary compounds have been shown to be effective in overcoming bacterial resistance mechanisms. For additional information, please visit: http://www.agilesci.com.